{"protocolSection": {"identificationModule": {"nctId": "NCT01353508", "orgStudyIdInfo": {"id": "CLCZ696B2223"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers", "officialTitle": "A Randomized, Double-blind, Controlled, Crossover Study to Evaluate the Sodium Excretion of LCZ696 in Patients With Stable Heart Failure, in Patients With Hypertension, and in Healthy Volunteers"}, "statusModule": {"statusVerifiedDate": "2015-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03"}, "primaryCompletionDateStruct": {"date": "2012-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-03-16", "studyFirstSubmitQcDate": "2011-05-12", "studyFirstPostDateStruct": {"date": "2011-05-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-15", "resultsFirstSubmitQcDate": "2015-10-20", "resultsFirstPostDateStruct": {"date": "2015-11-23", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-01-21", "dispFirstSubmitQcDate": "2014-01-21", "dispFirstPostDateStruct": {"date": "2014-02-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-20", "lastUpdatePostDateStruct": {"date": "2015-11-23", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "Assess mechanism of action of LCZ696 related to sodium excretion."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Sodium excretion,", "LCZ696"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 32, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696 to Valsartan - Heart Failure (HF) cohort", "type": "EXPERIMENTAL", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.", "interventionNames": ["Drug: LCZ696", "Drug: Valsartan"]}, {"label": "Valsartan to LCZ696 - HF Cohort", "type": "EXPERIMENTAL", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.", "interventionNames": ["Drug: LCZ696", "Drug: Valsartan"]}, {"label": "LCZ696 to Valsartan - Hypertension (HTN) cohort", "type": "EXPERIMENTAL", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.", "interventionNames": ["Drug: LCZ696", "Drug: Valsartan"]}, {"label": "Valsartan to LCZ696 - HTN cohort", "type": "EXPERIMENTAL", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.", "interventionNames": ["Drug: LCZ696", "Drug: Valsartan"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "200 mg and 400 mg tablets", "armGroupLabels": ["LCZ696 to Valsartan - Heart Failure (HF) cohort", "LCZ696 to Valsartan - Hypertension (HTN) cohort", "Valsartan to LCZ696 - HF Cohort", "Valsartan to LCZ696 - HTN cohort"]}, {"type": "DRUG", "name": "Valsartan", "description": "160 mg tablets", "armGroupLabels": ["LCZ696 to Valsartan - Heart Failure (HF) cohort", "LCZ696 to Valsartan - Hypertension (HTN) cohort", "Valsartan to LCZ696 - HF Cohort", "Valsartan to LCZ696 - HTN cohort"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "24-hour Urinary Sodium Excretion", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).", "timeFrame": "day 1"}, {"measure": "Cumulative 7-day Urinary Sodium Excretion", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).", "timeFrame": "7 day-cummulative (days 1 through 7)"}], "secondaryOutcomes": [{"measure": "24-hour Diuresis", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.", "timeFrame": "day 1"}, {"measure": "7-day Cumulative Diuresis", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.", "timeFrame": "7-day cumulative (days 1 through 7)"}, {"measure": "Urinary Cyclic Guanosine Monophosphate (cGMP) Excretion Over 24 Hours", "description": "cGMP was analyzed at a central laboratory. The measure type used for this OM was Geometric LSM.", "timeFrame": "day 1, day 6, day 7"}, {"measure": "Percent Change From Baseline in Plasma Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) Biomarker", "description": "MR-proANP was analyzed at a central laboratory.", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 2, 4, 6 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in Brain Natriuretic Peptide (BNP) Biomarker", "description": "BNP was analyzed at a central laboratory.", "timeFrame": "0.5, 1, 2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in Mid-regional Pro-adrenomedullin (MR-proADM) Biomarker", "description": "MR-proADM was analyzed at a central laboratory.", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in C-type Natriuretic Peptide (proCNP) Biomarker", "description": "ProCNP was analyzed at a central laboratory.", "timeFrame": "2, 4, 6, 8 and 12 hours post dose on day 1; day 2; 0, 4, 6, 8 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in C-terminal-proendothelin-1 (CT-proET-1) Biomarker", "description": "CT-proET-1 was analyzed at a central laboratory.", "timeFrame": "12 hours post dose on day 1; 24 hours post dose on day 2; 0 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in N-terminal-proBNP (NT-proBNP) Biomarker", "description": "NT-proBNP was analyzed at a central laboratory.", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in Aldosterone Biomarker", "description": "Aldosterone was analyzed at a central laboratory.", "timeFrame": "6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 6 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in Urinary Electrolyte Excretion (Sodium, Potassium, Chloride and Calcium)", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium, potassium, albumin and calcium were measured.", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7"}, {"measure": "Percent Change From Baseline in Blood Plasma Creatinine", "description": "Blood plasma creatinine was analyzed at a central laboratory.", "timeFrame": "4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7"}, {"measure": "Glomerular Filtration Rate (GFR) Over Time", "description": "GFR was used as a measure of renal function.", "timeFrame": "0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7"}, {"measure": "Renal Blood Flow (RBF) Over Time", "description": "RBF was used as a measure of renal function.", "timeFrame": "0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7"}, {"measure": "Supine Systolic Blood Pressure", "description": "Systolic blood pressure measurements were taken.", "timeFrame": "0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7"}, {"measure": "Supine Diastolic Blood Pressure", "description": "Diastolic blood pressure measurements were taken.", "timeFrame": "0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7"}, {"measure": "Supine Pulse Rate", "description": "Pulse rate measurements were taken.", "timeFrame": "0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with heart failure: documented NYHA class II-III heart failure\n* Patients with hypertension: stable hypertensive medication for the preceding 2 months\n\nExclusion Criteria:\n\n* Women of childbearing potential\n* History of recent myocardial infarction\n* History of dialysis or renal transplant\n* Patients with type 1 diabetes mellitus", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "117198", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "In each of the HF and HTN cohorts, 16 participants (total = 32) received LCZ696 or Valsartan in period 1. Then, there was a cross-over where participants received LCZ96 or Valsartan in period 2.", "groups": [{"id": "FG000", "title": "LCZ696 to Valsartan - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "FG001", "title": "Valsartan to LCZ696 - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "FG002", "title": "LCZ696 to Valsartan - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "FG003", "title": "Valsartan to LCZ696 - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "periods": [{"title": "Period 1 - First Intervention (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}, {"title": "Period 2 - Second Intervention (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696 to Valsartan - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "BG001", "title": "Valsartan to LCZ696 - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "BG002", "title": "LCZ696 to Valsartan - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "BG003", "title": "Valsartan to LCZ696 - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "32"}]}], "measures": [{"title": "Age, Continuous", "description": "Age mean and standard deviation (SD) for HF cohort was 65.4 (9.57); age mean and SD for HTN cohort was 58.8 (8.15)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63.3", "spread": "10.15"}, {"groupId": "BG001", "value": "67.6", "spread": "9.07"}, {"groupId": "BG002", "value": "58.0", "spread": "8.02"}, {"groupId": "BG003", "value": "61.6", "spread": "8.40"}, {"groupId": "BG004", "value": "62.6", "spread": "8.86"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "24-hour Urinary Sodium Excretion", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmol/24 hours", "timeFrame": "day 1", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "220.58", "lowerLimit": "182.64", "upperLimit": "266.41"}, {"groupId": "OG001", "value": "198.73", "lowerLimit": "163.50", "upperLimit": "241.56"}, {"groupId": "OG002", "value": "177.40", "lowerLimit": "152.65", "upperLimit": "206.15"}, {"groupId": "OG003", "value": "146.18", "lowerLimit": "126.42", "upperLimit": "169.03"}]}]}]}, {"type": "PRIMARY", "title": "Cumulative 7-day Urinary Sodium Excretion", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium concentration was measured. The measure type used for this outcome measure (OM) was Geometric Least square Means (LSM).", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmol/7 days", "timeFrame": "7 day-cummulative (days 1 through 7)", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1020.57", "lowerLimit": "903.47", "upperLimit": "1152.84"}, {"groupId": "OG001", "value": "1114.18", "lowerLimit": "983.37", "upperLimit": "1262.39"}, {"groupId": "OG002", "value": "906.81", "lowerLimit": "839.94", "upperLimit": "979.00"}, {"groupId": "OG003", "value": "943.26", "lowerLimit": "873.62", "upperLimit": "1018.45"}]}]}]}, {"type": "SECONDARY", "title": "24-hour Diuresis", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mL/24 hours", "timeFrame": "day 1", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3199.37", "lowerLimit": "2662.17", "upperLimit": "3844.96"}, {"groupId": "OG001", "value": "2874.36", "lowerLimit": "2375.61", "upperLimit": "3477.82"}, {"groupId": "OG002", "value": "3382.94", "lowerLimit": "2859.86", "upperLimit": "4001.70"}, {"groupId": "OG003", "value": "2393.61", "lowerLimit": "2034.84", "upperLimit": "2815.64"}]}]}]}, {"type": "SECONDARY", "title": "7-day Cumulative Diuresis", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, urine volume was measured. The measure type used for this OM was Geometric LSM.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mL", "timeFrame": "7-day cumulative (days 1 through 7)", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12347.92", "lowerLimit": "10842.81", "upperLimit": "14062.48"}, {"groupId": "OG001", "value": "13180.02", "lowerLimit": "11539.55", "upperLimit": "15053.71"}, {"groupId": "OG002", "value": "16980.05", "lowerLimit": "15627.59", "upperLimit": "18449.54"}, {"groupId": "OG003", "value": "15265.35", "lowerLimit": "14048.28", "upperLimit": "16587.87"}]}]}]}, {"type": "SECONDARY", "title": "Urinary Cyclic Guanosine Monophosphate (cGMP) Excretion Over 24 Hours", "description": "cGMP was analyzed at a central laboratory. The measure type used for this OM was Geometric LSM.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "nmol/24 hours", "timeFrame": "day 1, day 6, day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "1851.79", "lowerLimit": "1504.96", "upperLimit": "2278.56"}, {"groupId": "OG001", "value": "884.99", "lowerLimit": "713.93", "upperLimit": "1097.03"}, {"groupId": "OG002", "value": "1085.76", "lowerLimit": "867.64", "upperLimit": "1358.71"}, {"groupId": "OG003", "value": "557.53", "lowerLimit": "448.87", "upperLimit": "692.51"}]}]}, {"title": "Day 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "1467.67", "lowerLimit": "1153.25", "upperLimit": "1867.79"}, {"groupId": "OG001", "value": "865.62", "lowerLimit": "674.39", "upperLimit": "1111.07"}, {"groupId": "OG002", "value": "863.32", "lowerLimit": "707.64", "upperLimit": "1053.25"}, {"groupId": "OG003", "value": "562.11", "lowerLimit": "460.85", "upperLimit": "685.63"}]}]}, {"title": "Day 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "1571.02", "lowerLimit": "1331.84", "upperLimit": "1853.15"}, {"groupId": "OG001", "value": "859.07", "lowerLimit": "723.03", "upperLimit": "1020.72"}, {"groupId": "OG002", "value": "1107.04", "lowerLimit": "869.95", "upperLimit": "1408.76"}, {"groupId": "OG003", "value": "603.90", "lowerLimit": "474.68", "upperLimit": "768.30"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Plasma Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) Biomarker", "description": "MR-proANP was analyzed at a central laboratory.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 2, 4, 6 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.04", "lowerLimit": "-12.21", "upperLimit": "-1.87"}, {"groupId": "OG001", "value": "2.08", "lowerLimit": "-3.48", "upperLimit": "7.63"}, {"groupId": "OG002", "value": "-10.11", "lowerLimit": "-17.41", "upperLimit": "-2.82"}, {"groupId": "OG003", "value": "-1.66", "lowerLimit": "-7.99", "upperLimit": "4.68"}]}]}, {"title": "Day 1, 4.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.39", "lowerLimit": "-24.68", "upperLimit": "-10.10"}, {"groupId": "OG001", "value": "-6.74", "lowerLimit": "-14.32", "upperLimit": "0.84"}, {"groupId": "OG002", "value": "-12.68", "lowerLimit": "-25.45", "upperLimit": "0.08"}, {"groupId": "OG003", "value": "-7.33", "lowerLimit": "-19.27", "upperLimit": "4.61"}]}]}, {"title": "Day 1, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.99", "lowerLimit": "-31.64", "upperLimit": "-16.33"}, {"groupId": "OG001", "value": "-10.16", "lowerLimit": "-18.08", "upperLimit": "-2.23"}, {"groupId": "OG002", "value": "-17.82", "lowerLimit": "-25.16", "upperLimit": "-10.48"}, {"groupId": "OG003", "value": "-4.52", "lowerLimit": "-11.60", "upperLimit": "2.56"}]}]}, {"title": "Day 1, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.58", "lowerLimit": "-38.93", "upperLimit": "-16.22"}, {"groupId": "OG001", "value": "-7.48", "lowerLimit": "-19.26", "upperLimit": "4.29"}, {"groupId": "OG002", "value": "-19.77", "lowerLimit": "-32.56", "upperLimit": "-6.98"}, {"groupId": "OG003", "value": "-15.20", "lowerLimit": "-27.10", "upperLimit": "-3.31"}]}]}, {"title": "Day 2, 24.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-25.13", "lowerLimit": "-35.53", "upperLimit": "-14.73"}, {"groupId": "OG001", "value": "-14.53", "lowerLimit": "-25.28", "upperLimit": "-3.78"}, {"groupId": "OG002", "value": "-17.30", "lowerLimit": "-33.46", "upperLimit": "-1.13"}, {"groupId": "OG003", "value": "-9.45", "lowerLimit": "-24.39", "upperLimit": "5.50"}]}]}, {"title": "Day 7, 0.0 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.27", "lowerLimit": "-29.72", "upperLimit": "-12.81"}, {"groupId": "OG001", "value": "-2.54", "lowerLimit": "-11.30", "upperLimit": "6.21"}, {"groupId": "OG002", "value": "-16.03", "lowerLimit": "-28.52", "upperLimit": "-3.53"}, {"groupId": "OG003", "value": "0.44", "lowerLimit": "-11.59", "upperLimit": "12.46"}]}]}, {"title": "Day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.35", "lowerLimit": "-35.18", "upperLimit": "-13.52"}, {"groupId": "OG001", "value": "1.64", "lowerLimit": "-9.62", "upperLimit": "12.91"}, {"groupId": "OG002", "value": "-19.34", "lowerLimit": "-31.20", "upperLimit": "-7.49"}, {"groupId": "OG003", "value": "-2.56", "lowerLimit": "-13.90", "upperLimit": "8.78"}]}]}, {"title": "Day 7, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.40", "lowerLimit": "-33.98", "upperLimit": "-12.82"}, {"groupId": "OG001", "value": "-3.53", "lowerLimit": "-14.54", "upperLimit": "7.48"}, {"groupId": "OG002", "value": "-20.84", "lowerLimit": "-33.62", "upperLimit": "-8.05"}, {"groupId": "OG003", "value": "-1.98", "lowerLimit": "-14.25", "upperLimit": "10.28"}]}]}, {"title": "Day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.95", "lowerLimit": "-33.10", "upperLimit": "-8.80"}, {"groupId": "OG001", "value": "-12.65", "lowerLimit": "-25.27", "upperLimit": "-0.03"}, {"groupId": "OG002", "value": "-23.09", "lowerLimit": "-35.90", "upperLimit": "-10.28"}, {"groupId": "OG003", "value": "-10.27", "lowerLimit": "-22.61", "upperLimit": "2.06"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Brain Natriuretic Peptide (BNP) Biomarker", "description": "BNP was analyzed at a central laboratory.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "0.5, 1, 2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 0.5 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.32", "lowerLimit": "-70.26", "upperLimit": "214.90"}, {"groupId": "OG001", "value": "-8.93", "lowerLimit": "-151.85", "upperLimit": "133.99"}, {"groupId": "OG002", "value": "-10.75", "lowerLimit": "-28.59", "upperLimit": "7.08"}, {"groupId": "OG003", "value": "-5.94", "lowerLimit": "-23.59", "upperLimit": "11.71"}]}]}, {"title": "Day 1, 1.0 hr post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "121.85", "lowerLimit": "-86.02", "upperLimit": "329.72"}, {"groupId": "OG001", "value": "-0.83", "lowerLimit": "-209.19", "upperLimit": "207.53"}, {"groupId": "OG002", "value": "1218.56", "lowerLimit": "-760.23", "upperLimit": "3197.35"}, {"groupId": "OG003", "value": "-33.19", "lowerLimit": "-1865.92", "upperLimit": "1799.53"}]}]}, {"title": "Day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "176.35", "lowerLimit": "-85.34", "upperLimit": "438.04"}, {"groupId": "OG001", "value": "21.92", "lowerLimit": "-215.63", "upperLimit": "259.47"}, {"groupId": "OG002", "value": "31.10", "lowerLimit": "8.44", "upperLimit": "53.76"}, {"groupId": "OG003", "value": "-0.38", "lowerLimit": "-21.37", "upperLimit": "20.61"}]}]}, {"title": "Day 1, 4.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.12", "lowerLimit": "30.22", "upperLimit": "70.02"}, {"groupId": "OG001", "value": "-1.78", "lowerLimit": "-21.01", "upperLimit": "17.44"}, {"groupId": "OG002", "value": "38.82", "lowerLimit": "18.71", "upperLimit": "58.92"}, {"groupId": "OG003", "value": "11.06", "lowerLimit": "-7.56", "upperLimit": "29.68"}]}]}, {"title": "Day 1, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.62", "lowerLimit": "-10.46", "upperLimit": "271.70"}, {"groupId": "OG001", "value": "11.09", "lowerLimit": "-130.33", "upperLimit": "152.51"}, {"groupId": "OG002", "value": "68.23", "lowerLimit": "11.48", "upperLimit": "124.97"}, {"groupId": "OG003", "value": "7.97", "lowerLimit": "-44.59", "upperLimit": "60.52"}]}]}, {"title": "Day 1, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "90.58", "lowerLimit": "28.51", "upperLimit": "152.66"}, {"groupId": "OG001", "value": "30.07", "lowerLimit": "-32.15", "upperLimit": "92.29"}, {"groupId": "OG002", "value": "85.93", "lowerLimit": "23.34", "upperLimit": "148.52"}, {"groupId": "OG003", "value": "8.51", "lowerLimit": "-48.97", "upperLimit": "65.99"}]}]}, {"title": "Day 2, 24 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "102.88", "lowerLimit": "-84.18", "upperLimit": "289.93"}, {"groupId": "OG001", "value": "5.18", "lowerLimit": "-174.46", "upperLimit": "184.81"}, {"groupId": "OG002", "value": "-0.66", "lowerLimit": "-31.34", "upperLimit": "30.02"}, {"groupId": "OG003", "value": "-20.61", "lowerLimit": "-47.16", "upperLimit": "5.94"}]}]}, {"title": "Day 7, 0.0 hr", "categories": [{"measurements": [{"groupId": "OG000", "value": "190.96", "lowerLimit": "-100.59", "upperLimit": "482.51"}, {"groupId": "OG001", "value": "27.75", "lowerLimit": "-264.49", "upperLimit": "320.00"}, {"groupId": "OG002", "value": "14.20", "lowerLimit": "-28.81", "upperLimit": "57.21"}, {"groupId": "OG003", "value": "-7.19", "lowerLimit": "-48.17", "upperLimit": "33.79"}]}]}, {"title": "Day 7, 4.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "220.38", "lowerLimit": "-72.28", "upperLimit": "513.04"}, {"groupId": "OG001", "value": "34.44", "lowerLimit": "-249.44", "upperLimit": "318.31"}, {"groupId": "OG002", "value": "34.92", "lowerLimit": "-6.58", "upperLimit": "76.42"}, {"groupId": "OG003", "value": "5.20", "lowerLimit": "-34.59", "upperLimit": "44.99"}]}]}, {"title": "Day 7, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "195.06", "lowerLimit": "-94.90", "upperLimit": "485.02"}, {"groupId": "OG001", "value": "46.75", "lowerLimit": "-257.14", "upperLimit": "350.63"}, {"groupId": "OG002", "value": "7.78", "lowerLimit": "-33.49", "upperLimit": "49.04"}, {"groupId": "OG003", "value": "7.82", "lowerLimit": "-29.68", "upperLimit": "45.32"}]}]}, {"title": "Day 7, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "236.05", "lowerLimit": "-173.38", "upperLimit": "645.47"}, {"groupId": "OG001", "value": "70.31", "lowerLimit": "-334.37", "upperLimit": "474.99"}, {"groupId": "OG002", "value": "38.45", "lowerLimit": "-13.98", "upperLimit": "90.88"}, {"groupId": "OG003", "value": "25.79", "lowerLimit": "-24.48", "upperLimit": "76.06"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Mid-regional Pro-adrenomedullin (MR-proADM) Biomarker", "description": "MR-proADM was analyzed at a central laboratory.", "populationDescription": "The HF arms only of the Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis. MR-proADM is considered a biomarker for HF only; therefore, the HTN cohort was not assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.04", "lowerLimit": "-0.34", "upperLimit": "16.42"}, {"groupId": "OG001", "value": "-2.87", "lowerLimit": "-11.53", "upperLimit": "5.79"}]}]}, {"title": "Day 1, 4.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.22", "lowerLimit": "11.38", "upperLimit": "31.06"}, {"groupId": "OG001", "value": "-8.22", "lowerLimit": "-18.03", "upperLimit": "1.59"}]}]}, {"title": "Day 1, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.18", "lowerLimit": "10.05", "upperLimit": "30.31"}, {"groupId": "OG001", "value": "-8.81", "lowerLimit": "-18.90", "upperLimit": "1.27"}]}]}, {"title": "Day 1, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.70", "lowerLimit": "22.25", "upperLimit": "59.15"}, {"groupId": "OG001", "value": "7.61", "lowerLimit": "-10.84", "upperLimit": "26.05"}]}]}, {"title": "Day 2, 24 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "57.28", "lowerLimit": "42.29", "upperLimit": "72.26"}, {"groupId": "OG001", "value": "0.72", "lowerLimit": "-14.26", "upperLimit": "15.70"}]}]}, {"title": "Day 7, 0.0 hrs", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.28", "lowerLimit": "47.35", "upperLimit": "75.21"}, {"groupId": "OG001", "value": "1.38", "lowerLimit": "-12.07", "upperLimit": "14.83"}]}]}, {"title": "Day 7, 4.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.71", "lowerLimit": "39.67", "upperLimit": "63.74"}, {"groupId": "OG001", "value": "-5.27", "lowerLimit": "-16.90", "upperLimit": "6.36"}]}]}, {"title": "Day 7, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "48.22", "lowerLimit": "36.26", "upperLimit": "60.19"}, {"groupId": "OG001", "value": "-3.63", "lowerLimit": "-14.89", "upperLimit": "7.64"}]}]}, {"title": "Day 7, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.45", "lowerLimit": "50.70", "upperLimit": "88.20"}, {"groupId": "OG001", "value": "2.15", "lowerLimit": "-16.60", "upperLimit": "20.90"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in C-type Natriuretic Peptide (proCNP) Biomarker", "description": "ProCNP was analyzed at a central laboratory.", "populationDescription": "The HF arms only of the Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis. MR-proADM is considered a biomarker for HF only; therefore, the HTN cohort was not assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "2, 4, 6, 8 and 12 hours post dose on day 1; day 2; 0, 4, 6, 8 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Day 1, 2.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.35", "lowerLimit": "-6.33", "upperLimit": "7.03"}, {"groupId": "OG001", "value": "-1.01", "lowerLimit": "-8.16", "upperLimit": "6.13"}]}]}, {"title": "Day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.58", "lowerLimit": "19.36", "upperLimit": "49.79"}, {"groupId": "OG001", "value": "-6.02", "lowerLimit": "-22.28", "upperLimit": "10.25"}]}]}, {"title": "Day 1, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "67.85", "lowerLimit": "42.32", "upperLimit": "93.37"}, {"groupId": "OG001", "value": "-16.19", "lowerLimit": "-43.85", "upperLimit": "11.48"}]}]}, {"title": "Day 1, 8.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "123.75", "lowerLimit": "87.53", "upperLimit": "159.98"}, {"groupId": "OG001", "value": "-9.87", "lowerLimit": "-48.59", "upperLimit": "28.86"}]}]}, {"title": "Day 1, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "190.36", "lowerLimit": "148.95", "upperLimit": "231.78"}, {"groupId": "OG001", "value": "15.55", "lowerLimit": "-29.00", "upperLimit": "60.09"}]}]}, {"title": "Day 2, 24 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "218.81", "lowerLimit": "163.62", "upperLimit": "274.01"}, {"groupId": "OG001", "value": "4.99", "lowerLimit": "-54.79", "upperLimit": "64.78"}]}]}, {"title": "Day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "244.20", "lowerLimit": "186.26", "upperLimit": "302.14"}, {"groupId": "OG001", "value": "0.09", "lowerLimit": "-61.85", "upperLimit": "62.04"}]}]}, {"title": "Day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "216.61", "lowerLimit": "159.66", "upperLimit": "273.56"}, {"groupId": "OG001", "value": "-8.94", "lowerLimit": "-69.82", "upperLimit": "51.95"}]}]}, {"title": "Day 7, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "211.21", "lowerLimit": "151.36", "upperLimit": "271.07"}, {"groupId": "OG001", "value": "-18.17", "lowerLimit": "-82.15", "upperLimit": "45.82"}]}]}, {"title": "Day 7, 8.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "241.99", "lowerLimit": "181.22", "upperLimit": "302.76"}, {"groupId": "OG001", "value": "-11.30", "lowerLimit": "-76.27", "upperLimit": "53.67"}]}]}, {"title": "Day 7, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "278.58", "lowerLimit": "214.45", "upperLimit": "342.71"}, {"groupId": "OG001", "value": "0.88", "lowerLimit": "-67.68", "upperLimit": "69.44"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in C-terminal-proendothelin-1 (CT-proET-1) Biomarker", "description": "CT-proET-1 was analyzed at a central laboratory.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "12 hours post dose on day 1; 24 hours post dose on day 2; 0 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.39", "lowerLimit": "26.14", "upperLimit": "46.65"}, {"groupId": "OG001", "value": "2.51", "lowerLimit": "-8.14", "upperLimit": "13.16"}, {"groupId": "OG002", "value": "108.87", "lowerLimit": "5.82", "upperLimit": "211.92"}, {"groupId": "OG003", "value": "54.07", "lowerLimit": "-38.42", "upperLimit": "146.57"}]}]}, {"title": "Day 2, 24.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.44", "lowerLimit": "19.41", "upperLimit": "45.47"}, {"groupId": "OG001", "value": "11.41", "lowerLimit": "-2.76", "upperLimit": "25.59"}, {"groupId": "OG002", "value": "123.45", "lowerLimit": "36.65", "upperLimit": "210.25"}, {"groupId": "OG003", "value": "38.70", "lowerLimit": "-41.78", "upperLimit": "119.19"}]}]}, {"title": "Day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.98", "lowerLimit": "19.53", "upperLimit": "44.42"}, {"groupId": "OG001", "value": "0.62", "lowerLimit": "-11.85", "upperLimit": "13.09"}, {"groupId": "OG002", "value": "94.76", "lowerLimit": "17.45", "upperLimit": "172.06"}, {"groupId": "OG003", "value": "41.77", "lowerLimit": "-32.97", "upperLimit": "116.50"}]}]}, {"title": "Day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.75", "lowerLimit": "26.81", "upperLimit": "56.69"}, {"groupId": "OG001", "value": "7.05", "lowerLimit": "-8.97", "upperLimit": "23.08"}, {"groupId": "OG002", "value": "117.84", "lowerLimit": "30.76", "upperLimit": "204.92"}, {"groupId": "OG003", "value": "61.90", "lowerLimit": "-22.40", "upperLimit": "146.20"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in N-terminal-proBNP (NT-proBNP) Biomarker", "description": "NT-proBNP was analyzed at a central laboratory.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.06", "lowerLimit": "-1.80", "upperLimit": "7.92"}, {"groupId": "OG001", "value": "6.87", "lowerLimit": "1.87", "upperLimit": "11.88"}, {"groupId": "OG002", "value": "5.10", "lowerLimit": "-1.10", "upperLimit": "11.31"}, {"groupId": "OG003", "value": "8.32", "lowerLimit": "2.32", "upperLimit": "14.32"}]}]}, {"title": "Day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.68", "lowerLimit": "-5.30", "upperLimit": "10.66"}, {"groupId": "OG001", "value": "13.21", "lowerLimit": "5.02", "upperLimit": "21.40"}, {"groupId": "OG002", "value": "44.79", "lowerLimit": "-11.93", "upperLimit": "101.51"}, {"groupId": "OG003", "value": "22.14", "lowerLimit": "-32.65", "upperLimit": "76.93"}]}]}, {"title": "Day 1, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.71", "lowerLimit": "-8.15", "upperLimit": "15.57"}, {"groupId": "OG001", "value": "21.70", "lowerLimit": "9.59", "upperLimit": "33.80"}, {"groupId": "OG002", "value": "12.58", "lowerLimit": "-4.17", "upperLimit": "29.33"}, {"groupId": "OG003", "value": "21.21", "lowerLimit": "5.03", "upperLimit": "37.39"}]}]}, {"title": "Day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.15", "lowerLimit": "-3.58", "upperLimit": "37.89"}, {"groupId": "OG001", "value": "42.32", "lowerLimit": "20.94", "upperLimit": "63.70"}, {"groupId": "OG002", "value": "61.46", "lowerLimit": "3.83", "upperLimit": "119.09"}, {"groupId": "OG003", "value": "33.17", "lowerLimit": "-22.28", "upperLimit": "88.62"}]}]}, {"title": "Day 2, 24 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.85", "lowerLimit": "-35.37", "upperLimit": "-8.33"}, {"groupId": "OG001", "value": "23.51", "lowerLimit": "9.48", "upperLimit": "37.54"}, {"groupId": "OG002", "value": "8.61", "lowerLimit": "-20.73", "upperLimit": "37.95"}, {"groupId": "OG003", "value": "-4.41", "lowerLimit": "-32.64", "upperLimit": "23.81"}]}]}, {"title": "Day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.57", "lowerLimit": "-34.08", "upperLimit": "-5.05"}, {"groupId": "OG001", "value": "2.29", "lowerLimit": "-12.74", "upperLimit": "17.32"}, {"groupId": "OG002", "value": "-10.14", "lowerLimit": "-35.77", "upperLimit": "15.48"}, {"groupId": "OG003", "value": "-0.13", "lowerLimit": "-25.77", "upperLimit": "25.51"}]}]}, {"title": "Day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.60", "lowerLimit": "-30.67", "upperLimit": "1.47"}, {"groupId": "OG001", "value": "14.85", "lowerLimit": "-1.78", "upperLimit": "31.49"}, {"groupId": "OG002", "value": "-8.10", "lowerLimit": "-35.21", "upperLimit": "19.01"}, {"groupId": "OG003", "value": "19.83", "lowerLimit": "-7.29", "upperLimit": "46.95"}]}]}, {"title": "Day 7, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.05", "lowerLimit": "-32.53", "upperLimit": "2.43"}, {"groupId": "OG001", "value": "17.34", "lowerLimit": "-0.75", "upperLimit": "35.44"}, {"groupId": "OG002", "value": "-9.42", "lowerLimit": "-37.40", "upperLimit": "18.57"}, {"groupId": "OG003", "value": "20.47", "lowerLimit": "-6.63", "upperLimit": "47.58"}]}]}, {"title": "Day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.37", "lowerLimit": "-22.83", "upperLimit": "25.56"}, {"groupId": "OG001", "value": "46.05", "lowerLimit": "20.87", "upperLimit": "71.22"}, {"groupId": "OG002", "value": "12.22", "lowerLimit": "-26.18", "upperLimit": "50.62"}, {"groupId": "OG003", "value": "47.27", "lowerLimit": "8.85", "upperLimit": "85.68"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Aldosterone Biomarker", "description": "Aldosterone was analyzed at a central laboratory.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 6 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.15", "lowerLimit": "29.66", "upperLimit": "112.64"}, {"groupId": "OG001", "value": "-14.63", "lowerLimit": "-56.02", "upperLimit": "26.77"}, {"groupId": "OG002", "value": "90.51", "lowerLimit": "-39.10", "upperLimit": "220.12"}, {"groupId": "OG003", "value": "72.92", "lowerLimit": "-48.38", "upperLimit": "194.22"}]}]}, {"title": "Day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "208.06", "lowerLimit": "44.03", "upperLimit": "372.10"}, {"groupId": "OG001", "value": "8.36", "lowerLimit": "-155.05", "upperLimit": "171.77"}, {"groupId": "OG002", "value": "249.13", "lowerLimit": "4.30", "upperLimit": "493.96"}, {"groupId": "OG003", "value": "325.31", "lowerLimit": "96.75", "upperLimit": "553.86"}]}]}, {"title": "Day 2, 24.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "168.32", "lowerLimit": "65.01", "upperLimit": "271.63"}, {"groupId": "OG001", "value": "71.73", "lowerLimit": "-35.08", "upperLimit": "178.55"}, {"groupId": "OG002", "value": "438.28", "lowerLimit": "-67.61", "upperLimit": "944.17"}, {"groupId": "OG003", "value": "524.93", "lowerLimit": "55.45", "upperLimit": "994.41"}]}]}, {"title": "Day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "111.21", "lowerLimit": "16.31", "upperLimit": "206.11"}, {"groupId": "OG001", "value": "21.68", "lowerLimit": "-77.33", "upperLimit": "120.69"}, {"groupId": "OG002", "value": "49.91", "lowerLimit": "-12.58", "upperLimit": "112.40"}, {"groupId": "OG003", "value": "5.61", "lowerLimit": "-55.0", "upperLimit": "66.22"}]}]}, {"title": "Day 7, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.22", "lowerLimit": "7.48", "upperLimit": "122.95"}, {"groupId": "OG001", "value": "24.58", "lowerLimit": "-31.70", "upperLimit": "80.87"}, {"groupId": "OG002", "value": "24.47", "lowerLimit": "-104.07", "upperLimit": "153.01"}, {"groupId": "OG003", "value": "107.60", "lowerLimit": "-16.47", "upperLimit": "231.67"}]}]}, {"title": "Day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "238.32", "lowerLimit": "-46.10", "upperLimit": "522.74"}, {"groupId": "OG001", "value": "230.06", "lowerLimit": "-58.04", "upperLimit": "518.17"}, {"groupId": "OG002", "value": "147.89", "lowerLimit": "-4.40", "upperLimit": "300.19"}, {"groupId": "OG003", "value": "152.37", "lowerLimit": "4.74", "upperLimit": "300.00"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Urinary Electrolyte Excretion (Sodium, Potassium, Chloride and Calcium)", "description": "Urine was collected in 12-hour intervals, and of each pooled 24-hour (daily) sample, sodium, potassium, albumin and calcium were measured.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "2, 4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Calcium, day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "lowerLimit": "-1.24", "upperLimit": "1.13"}, {"groupId": "OG001", "value": "-1.40", "lowerLimit": "-2.62", "upperLimit": "-0.17"}, {"groupId": "OG002", "value": "0.51", "lowerLimit": "-1.00", "upperLimit": "2.01"}, {"groupId": "OG003", "value": "0.08", "lowerLimit": "-1.38", "upperLimit": "1.53"}]}]}, {"title": "Calcium, day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.19", "lowerLimit": "-3.78", "upperLimit": "-0.60"}, {"groupId": "OG001", "value": "-2.46", "lowerLimit": "-4.11", "upperLimit": "-0.81"}, {"groupId": "OG002", "value": "0.76", "lowerLimit": "-1.39", "upperLimit": "2.91"}, {"groupId": "OG003", "value": "0.27", "lowerLimit": "-1.79", "upperLimit": "2.33"}]}]}, {"title": "Calcium, day 1, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.69", "lowerLimit": "-5.19", "upperLimit": "-2.19"}, {"groupId": "OG001", "value": "-4.03", "lowerLimit": "-5.59", "upperLimit": "-2.48"}, {"groupId": "OG002", "value": "-2.22", "lowerLimit": "-3.89", "upperLimit": "-0.55"}, {"groupId": "OG003", "value": "-2.49", "lowerLimit": "-4.10", "upperLimit": "-0.89"}]}]}, {"title": "Calcium, day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.80", "lowerLimit": "-4.24", "upperLimit": "-1.37"}, {"groupId": "OG001", "value": "-1.34", "lowerLimit": "-2.83", "upperLimit": "0.16"}, {"groupId": "OG002", "value": "1.77", "lowerLimit": "-0.40", "upperLimit": "3.94"}, {"groupId": "OG003", "value": "0.82", "lowerLimit": "-1.27", "upperLimit": "2.91"}]}]}, {"title": "Calcium, day 2, 24 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.09", "lowerLimit": "-4.21", "upperLimit": "0.02"}, {"groupId": "OG001", "value": "0.44", "lowerLimit": "-1.72", "upperLimit": "2.60"}, {"groupId": "OG002", "value": "2.06", "lowerLimit": "-0.42", "upperLimit": "4.55"}, {"groupId": "OG003", "value": "1.34", "lowerLimit": "-1.06", "upperLimit": "3.73"}]}]}, {"title": "Calcium, day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.34", "lowerLimit": "-2.75", "upperLimit": "2.07"}, {"groupId": "OG001", "value": "-1.11", "lowerLimit": "-3.60", "upperLimit": "1.38"}, {"groupId": "OG002", "value": "-5.82", "lowerLimit": "-8.28", "upperLimit": "-3.36"}, {"groupId": "OG003", "value": "-6.19", "lowerLimit": "-8.65", "upperLimit": "-3.73"}]}]}, {"title": "Calcium, day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.45", "lowerLimit": "-4.09", "upperLimit": "-0.81"}, {"groupId": "OG001", "value": "-2.17", "lowerLimit": "-3.87", "upperLimit": "-0.47"}, {"groupId": "OG002", "value": "-8.46", "lowerLimit": "-10.95", "upperLimit": "-5.98"}, {"groupId": "OG003", "value": "-7.42", "lowerLimit": "-9.90", "upperLimit": "-4.94"}]}]}, {"title": "Calcium, day 7, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.30", "lowerLimit": "-5.65", "upperLimit": "-2.95"}, {"groupId": "OG001", "value": "-3.53", "lowerLimit": "-4.93", "upperLimit": "-2.12"}, {"groupId": "OG002", "value": "-9.12", "lowerLimit": "-11.54", "upperLimit": "-6.70"}, {"groupId": "OG003", "value": "-9.89", "lowerLimit": "-12.32", "upperLimit": "-7.47"}]}]}, {"title": "Calcium, day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.41", "lowerLimit": "-4.94", "upperLimit": "-1.88"}, {"groupId": "OG001", "value": "-1.27", "lowerLimit": "-2.86", "upperLimit": "0.32"}, {"groupId": "OG002", "value": "-4.63", "lowerLimit": "-6.89", "upperLimit": "-2.36"}, {"groupId": "OG003", "value": "-4.99", "lowerLimit": "-7.25", "upperLimit": "-2.73"}]}]}, {"title": "Chloride, day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.33", "lowerLimit": "-1.05", "upperLimit": "0.39"}, {"groupId": "OG001", "value": "-0.47", "lowerLimit": "-1.22", "upperLimit": "0.28"}, {"groupId": "OG002", "value": "-0.35", "lowerLimit": "-0.96", "upperLimit": "0.27"}, {"groupId": "OG003", "value": "0.22", "lowerLimit": "-0.38", "upperLimit": "0.81"}]}]}, {"title": "Chloride, day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.35", "lowerLimit": "-2.07", "upperLimit": "-0.64"}, {"groupId": "OG001", "value": "-0.61", "lowerLimit": "-1.36", "upperLimit": "0.14"}, {"groupId": "OG002", "value": "0.05", "lowerLimit": "-0.62", "upperLimit": "0.72"}, {"groupId": "OG003", "value": "0.41", "lowerLimit": "-0.23", "upperLimit": "1.05"}]}]}, {"title": "Chloride, day 1, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "lowerLimit": "-1.35", "upperLimit": "0.03"}, {"groupId": "OG001", "value": "-0.42", "lowerLimit": "-1.14", "upperLimit": "0.30"}, {"groupId": "OG002", "value": "-0.48", "lowerLimit": "-1.15", "upperLimit": "0.19"}, {"groupId": "OG003", "value": "0.05", "lowerLimit": "-0.59", "upperLimit": "0.70"}]}]}, {"title": "Chloride, day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "lowerLimit": "-0.49", "upperLimit": "1.41"}, {"groupId": "OG001", "value": "1.44", "lowerLimit": "0.45", "upperLimit": "2.42"}, {"groupId": "OG002", "value": "-0.93", "lowerLimit": "-1.70", "upperLimit": "-0.16"}, {"groupId": "OG003", "value": "-0.15", "lowerLimit": "-0.92", "upperLimit": "0.62"}]}]}, {"title": "Chloride, day 2, 24 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.49", "lowerLimit": "-0.23", "upperLimit": "1.22"}, {"groupId": "OG001", "value": "0.73", "lowerLimit": "-0.02", "upperLimit": "1.48"}, {"groupId": "OG002", "value": "0.11", "lowerLimit": "-0.82", "upperLimit": "1.04"}, {"groupId": "OG003", "value": "0.58", "lowerLimit": "-0.34", "upperLimit": "1.51"}]}]}, {"title": "Chloride, day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.46", "lowerLimit": "0.40", "upperLimit": "2.53"}, {"groupId": "OG001", "value": "1.28", "lowerLimit": "0.19", "upperLimit": "2.37"}, {"groupId": "OG002", "value": "0.89", "lowerLimit": "0.17", "upperLimit": "1.62"}, {"groupId": "OG003", "value": "0.63", "lowerLimit": "-0.09", "upperLimit": "1.36"}]}]}, {"title": "Chloride, day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.47", "lowerLimit": "-0.96", "upperLimit": "1.89"}, {"groupId": "OG001", "value": "0.22", "lowerLimit": "-1.26", "upperLimit": "1.69"}, {"groupId": "OG002", "value": "-0.05", "lowerLimit": "-0.86", "upperLimit": "0.75"}, {"groupId": "OG003", "value": "0.28", "lowerLimit": "-0.50", "upperLimit": "1.07"}]}]}, {"title": "Chloride, day 7, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "lowerLimit": "-0.29", "upperLimit": "2.03"}, {"groupId": "OG001", "value": "1.32", "lowerLimit": "0.11", "upperLimit": "2.52"}, {"groupId": "OG002", "value": "-0.21", "lowerLimit": "-1.00", "upperLimit": "0.58"}, {"groupId": "OG003", "value": "-0.86", "lowerLimit": "-1.68", "upperLimit": "-0.04"}]}]}, {"title": "Chloride, day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.98", "lowerLimit": "-0.12", "upperLimit": "2.09"}, {"groupId": "OG001", "value": "1.20", "lowerLimit": "0.06", "upperLimit": "2.35"}, {"groupId": "OG002", "value": "-1.16", "lowerLimit": "-2.08", "upperLimit": "-0.25"}, {"groupId": "OG003", "value": "-1.48", "lowerLimit": "-2.43", "upperLimit": "-0.53"}]}]}, {"title": "Potassium, day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.96", "lowerLimit": "-0.71", "upperLimit": "4.63"}, {"groupId": "OG001", "value": "-1.25", "lowerLimit": "-4.01", "upperLimit": "1.51"}, {"groupId": "OG002", "value": "-1.20", "lowerLimit": "-3.86", "upperLimit": "1.45"}, {"groupId": "OG003", "value": "1.69", "lowerLimit": "-0.86", "upperLimit": "4.24"}]}]}, {"title": "Potassium, day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.16", "lowerLimit": "-3.73", "upperLimit": "3.41"}, {"groupId": "OG001", "value": "-0.11", "lowerLimit": "-3.80", "upperLimit": "3.58"}, {"groupId": "OG002", "value": "0.42", "lowerLimit": "-6.10", "upperLimit": "6.95"}, {"groupId": "OG003", "value": "1.11", "lowerLimit": "-5.17", "upperLimit": "7.39"}]}]}, {"title": "Potassium, day 1, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.91", "lowerLimit": "-5.82", "upperLimit": "0.01"}, {"groupId": "OG001", "value": "-5.88", "lowerLimit": "-8.90", "upperLimit": "-2.87"}, {"groupId": "OG002", "value": "-0.63", "lowerLimit": "-8.29", "upperLimit": "7.02"}, {"groupId": "OG003", "value": "-2.61", "lowerLimit": "-10.00", "upperLimit": "4.79"}]}]}, {"title": "Potassium, day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.63", "lowerLimit": "-0.02", "upperLimit": "13.28"}, {"groupId": "OG001", "value": "15.27", "lowerLimit": "8.40", "upperLimit": "22.15"}, {"groupId": "OG002", "value": "18.57", "lowerLimit": "10.49", "upperLimit": "26.64"}, {"groupId": "OG003", "value": "19.96", "lowerLimit": "11.85", "upperLimit": "28.08"}]}]}, {"title": "Potassium, day 2, 24.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.06", "lowerLimit": "-1.44", "upperLimit": "5.56"}, {"groupId": "OG001", "value": "0.14", "lowerLimit": "-3.48", "upperLimit": "3.76"}, {"groupId": "OG002", "value": "7.70", "lowerLimit": "1.23", "upperLimit": "14.18"}, {"groupId": "OG003", "value": "7.00", "lowerLimit": "0.51", "upperLimit": "13.49"}]}]}, {"title": "Potassium, day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.06", "lowerLimit": "-2.80", "upperLimit": "4.93"}, {"groupId": "OG001", "value": "-1.55", "lowerLimit": "-5.55", "upperLimit": "2.45"}, {"groupId": "OG002", "value": "-0.47", "lowerLimit": "-4.70", "upperLimit": "3.76"}, {"groupId": "OG003", "value": "1.29", "lowerLimit": "-2.93", "upperLimit": "5.52"}]}]}, {"title": "Potassium, day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.16", "lowerLimit": "-5.21", "upperLimit": "0.89"}, {"groupId": "OG001", "value": "-2.93", "lowerLimit": "-6.08", "upperLimit": "0.22"}, {"groupId": "OG002", "value": "3.61", "lowerLimit": "-5.71", "upperLimit": "12.94"}, {"groupId": "OG003", "value": "0.28", "lowerLimit": "-8.60", "upperLimit": "9.16"}]}]}, {"title": "Potassium, day 7, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.23", "lowerLimit": "-6.47", "upperLimit": "0.00"}, {"groupId": "OG001", "value": "-5.16", "lowerLimit": "-8.49", "upperLimit": "-1.84"}, {"groupId": "OG002", "value": "-4.20", "lowerLimit": "-10.85", "upperLimit": "2.45"}, {"groupId": "OG003", "value": "-4.14", "lowerLimit": "-11.06", "upperLimit": "2.78"}]}]}, {"title": "Potassium, day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.22", "lowerLimit": "9.58", "upperLimit": "24.86"}, {"groupId": "OG001", "value": "12.32", "lowerLimit": "4.37", "upperLimit": "20.26"}, {"groupId": "OG002", "value": "18.19", "lowerLimit": "7.38", "upperLimit": "29.01"}, {"groupId": "OG003", "value": "19.28", "lowerLimit": "8.12", "upperLimit": "30.45"}]}]}, {"title": "Sodium, day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.09", "lowerLimit": "-1.68", "upperLimit": "-0.50"}, {"groupId": "OG001", "value": "-0.67", "lowerLimit": "-1.28", "upperLimit": "-0.05"}, {"groupId": "OG002", "value": "-0.63", "lowerLimit": "-1.10", "upperLimit": "-0.16"}, {"groupId": "OG003", "value": "-0.17", "lowerLimit": "-0.63", "upperLimit": "0.29"}]}]}, {"title": "Sodium, day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.82", "lowerLimit": "-2.52", "upperLimit": "-1.13"}, {"groupId": "OG001", "value": "-1.18", "lowerLimit": "-1.90", "upperLimit": "-0.45"}, {"groupId": "OG002", "value": "-0.18", "lowerLimit": "-0.84", "upperLimit": "0.48"}, {"groupId": "OG003", "value": "-0.04", "lowerLimit": "-0.67", "upperLimit": "0.59"}]}]}, {"title": "Sodium, day 1, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.47", "lowerLimit": "-2.09", "upperLimit": "-0.84"}, {"groupId": "OG001", "value": "-1.12", "lowerLimit": "-1.77", "upperLimit": "-0.47"}, {"groupId": "OG002", "value": "-0.62", "lowerLimit": "-1.20", "upperLimit": "-0.04"}, {"groupId": "OG003", "value": "-0.17", "lowerLimit": "-0.73", "upperLimit": "0.39"}]}]}, {"title": "Sodium, day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.17", "lowerLimit": "-0.74", "upperLimit": "0.39"}, {"groupId": "OG001", "value": "0.48", "lowerLimit": "-0.11", "upperLimit": "1.07"}, {"groupId": "OG002", "value": "-0.12", "lowerLimit": "-0.91", "upperLimit": "0.68"}, {"groupId": "OG003", "value": "0.14", "lowerLimit": "-0.66", "upperLimit": "0.93"}]}]}, {"title": "Sodium, day 2, 24.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "lowerLimit": "-0.78", "upperLimit": "0.84"}, {"groupId": "OG001", "value": "1.06", "lowerLimit": "0.22", "upperLimit": "1.90"}, {"groupId": "OG002", "value": "0.85", "lowerLimit": "0.24", "upperLimit": "1.45"}, {"groupId": "OG003", "value": "1.24", "lowerLimit": "0.63", "upperLimit": "1.84"}]}]}, {"title": "Sodium, day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.21", "lowerLimit": "0.23", "upperLimit": "2.18"}, {"groupId": "OG001", "value": "1.36", "lowerLimit": "0.35", "upperLimit": "2.37"}, {"groupId": "OG002", "value": "0.69", "lowerLimit": "0.05", "upperLimit": "1.33"}, {"groupId": "OG003", "value": "0.84", "lowerLimit": "0.20", "upperLimit": "1.48"}]}]}, {"title": "Sodium, day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "lowerLimit": "-1.46", "upperLimit": "0.95"}, {"groupId": "OG001", "value": "-0.89", "lowerLimit": "-2.14", "upperLimit": "0.37"}, {"groupId": "OG002", "value": "-0.81", "lowerLimit": "-1.57", "upperLimit": "-0.05"}, {"groupId": "OG003", "value": "-0.16", "lowerLimit": "-0.89", "upperLimit": "0.57"}]}]}, {"title": "Sodium, day 7, 6.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "lowerLimit": "-1.17", "upperLimit": "1.19"}, {"groupId": "OG001", "value": "-0.19", "lowerLimit": "-1.42", "upperLimit": "1.05"}, {"groupId": "OG002", "value": "-0.74", "lowerLimit": "-1.36", "upperLimit": "-0.13"}, {"groupId": "OG003", "value": "-0.86", "lowerLimit": "-1.49", "upperLimit": "-0.23"}]}]}, {"title": "Sodium, day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.34", "lowerLimit": "-0.62", "upperLimit": "1.29"}, {"groupId": "OG001", "value": "0.78", "lowerLimit": "-0.22", "upperLimit": "1.77"}, {"groupId": "OG002", "value": "-0.41", "lowerLimit": "-1.23", "upperLimit": "0.42"}, {"groupId": "OG003", "value": "-1.04", "lowerLimit": "-1.89", "upperLimit": "-0.20"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Blood Plasma Creatinine", "description": "Blood plasma creatinine was analyzed at a central laboratory.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage change", "timeFrame": "4, 6 and 12 hours post dose on day 1; 24 hours post dose on day 2; 0, 4, 6 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.06", "lowerLimit": "-9.03", "upperLimit": "-5.10"}, {"groupId": "OG001", "value": "-3.55", "lowerLimit": "-5.56", "upperLimit": "-1.54"}, {"groupId": "OG002", "value": "-7.48", "lowerLimit": "-9.28", "upperLimit": "-5.68"}, {"groupId": "OG003", "value": "-0.91", "lowerLimit": "-2.65", "upperLimit": "0.83"}]}]}, {"title": "Day 1, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.97", "lowerLimit": "-5.49", "upperLimit": "-0.46"}, {"groupId": "OG001", "value": "-0.07", "lowerLimit": "-2.67", "upperLimit": "2.54"}, {"groupId": "OG002", "value": "-1.72", "lowerLimit": "-5.41", "upperLimit": "1.96"}, {"groupId": "OG003", "value": "4.40", "lowerLimit": "0.84", "upperLimit": "7.95"}]}]}, {"title": "Day 1, 12.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.02", "lowerLimit": "-1.96", "upperLimit": "8.00"}, {"groupId": "OG001", "value": "5.36", "lowerLimit": "0.21", "upperLimit": "10.52"}, {"groupId": "OG002", "value": "6.22", "lowerLimit": "1.90", "upperLimit": "10.54"}, {"groupId": "OG003", "value": "9.23", "lowerLimit": "5.07", "upperLimit": "13.40"}]}]}, {"title": "Day 2, 24 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.73", "lowerLimit": "-1.37", "upperLimit": "8.83"}, {"groupId": "OG001", "value": "4.02", "lowerLimit": "-1.26", "upperLimit": "9.30"}, {"groupId": "OG002", "value": "13.64", "lowerLimit": "8.44", "upperLimit": "18.84"}, {"groupId": "OG003", "value": "6.18", "lowerLimit": "1.15", "upperLimit": "11.21"}]}]}, {"title": "Day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.24", "lowerLimit": "-6.71", "upperLimit": "15.19"}, {"groupId": "OG001", "value": "0.55", "lowerLimit": "-10.43", "upperLimit": "11.52"}, {"groupId": "OG002", "value": "1.76", "lowerLimit": "-1.74", "upperLimit": "5.27"}, {"groupId": "OG003", "value": "1.71", "lowerLimit": "-1.79", "upperLimit": "5.21"}]}]}, {"title": "Day 7, 4.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.47", "lowerLimit": "-8.56", "upperLimit": "5.63"}, {"groupId": "OG001", "value": "-5.09", "lowerLimit": "-12.26", "upperLimit": "2.07"}, {"groupId": "OG002", "value": "-3.02", "lowerLimit": "-6.71", "upperLimit": "0.68"}, {"groupId": "OG003", "value": "-1.28", "lowerLimit": "-4.98", "upperLimit": "2.41"}]}]}, {"title": "Day 7, 6.0 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.72", "lowerLimit": "-6.15", "upperLimit": "9.59"}, {"groupId": "OG001", "value": "-0.25", "lowerLimit": "-8.18", "upperLimit": "7.68"}, {"groupId": "OG002", "value": "0.48", "lowerLimit": "-3.44", "upperLimit": "4.40"}, {"groupId": "OG003", "value": "3.03", "lowerLimit": "-0.89", "upperLimit": "6.94"}]}]}, {"title": "Day 7, 12 hrs post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.03", "lowerLimit": "-3.02", "upperLimit": "19.07"}, {"groupId": "OG001", "value": "8.34", "lowerLimit": "-2.79", "upperLimit": "19.48"}, {"groupId": "OG002", "value": "9.33", "lowerLimit": "4.43", "upperLimit": "14.24"}, {"groupId": "OG003", "value": "4.55", "lowerLimit": "-0.35", "upperLimit": "9.46"}]}]}]}, {"type": "SECONDARY", "title": "Glomerular Filtration Rate (GFR) Over Time", "description": "GFR was used as a measure of renal function.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/min", "timeFrame": "0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.4", "spread": "43.27"}, {"groupId": "OG001", "value": "92.5", "spread": "97.37"}, {"groupId": "OG002", "value": "87.6", "spread": "64.27"}, {"groupId": "OG003", "value": "99.2", "spread": "66.36"}]}]}, {"title": "Day 1, 2 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "115.7", "spread": "57.89"}, {"groupId": "OG001", "value": "83.3", "spread": "46.57"}, {"groupId": "OG002", "value": "112.1", "spread": "63.30"}, {"groupId": "OG003", "value": "96.0", "spread": "44.23"}]}]}, {"title": "Day 1, 4 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "117.4", "spread": "75.09"}, {"groupId": "OG001", "value": "70.9", "spread": "36.64"}, {"groupId": "OG002", "value": "125.4", "spread": "95.33"}, {"groupId": "OG003", "value": "101.8", "spread": "65.34"}]}]}, {"title": "Day 1, 6 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "120.2", "spread": "68.73"}, {"groupId": "OG001", "value": "71.7", "spread": "37.27"}, {"groupId": "OG002", "value": "148.4", "spread": "138.66"}, {"groupId": "OG003", "value": "123.0", "spread": "60.62"}]}]}, {"title": "Day 7, 0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.7", "spread": "75.98"}, {"groupId": "OG001", "value": "87.8", "spread": "57.47"}, {"groupId": "OG002", "value": "96.8", "spread": "78.65"}, {"groupId": "OG003", "value": "83.2", "spread": "53.11"}]}]}, {"title": "Day 7, 2 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.9", "spread": "39.47"}, {"groupId": "OG001", "value": "83.1", "spread": "35.65"}, {"groupId": "OG002", "value": "133.5", "spread": "67.82"}, {"groupId": "OG003", "value": "91.4", "spread": "50.57"}]}]}, {"title": "Day 7, 4 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "89.6", "spread": "52.23"}, {"groupId": "OG001", "value": "94.6", "spread": "53.43"}, {"groupId": "OG002", "value": "151.7", "spread": "109.91"}, {"groupId": "OG003", "value": "111.3", "spread": "59.41"}]}]}, {"title": "Day 7, 6 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "86.9", "spread": "49.26"}, {"groupId": "OG001", "value": "126.6", "spread": "79.95"}, {"groupId": "OG002", "value": "111.5", "spread": "66.30"}, {"groupId": "OG003", "value": "165.2", "spread": "228.97"}]}]}]}, {"type": "SECONDARY", "title": "Renal Blood Flow (RBF) Over Time", "description": "RBF was used as a measure of renal function.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/min", "timeFrame": "0, 2, 4 and 6 hours post dose on day 1; 0, 2, 4 and 6 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "398.1", "spread": "221.24"}, {"groupId": "OG001", "value": "305.7", "spread": "159.44"}, {"groupId": "OG002", "value": "774.7", "spread": "893.23"}, {"groupId": "OG003", "value": "737.0", "spread": "323.14"}]}]}, {"title": "Day 1, 2 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "361.3", "spread": "171.80"}, {"groupId": "OG001", "value": "357.4", "spread": "218.28"}, {"groupId": "OG002", "value": "570.5", "spread": "212.67"}, {"groupId": "OG003", "value": "541.7", "spread": "179.20"}]}]}, {"title": "Day 1, 4 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "340.1", "spread": "169.87"}, {"groupId": "OG001", "value": "297.4", "spread": "219.83"}, {"groupId": "OG002", "value": "700.0", "spread": "408.73"}, {"groupId": "OG003", "value": "573.4", "spread": "287.14"}]}]}, {"title": "Day 1, 6 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "465.2", "spread": "276.84"}, {"groupId": "OG001", "value": "290.05", "spread": "138.30"}, {"groupId": "OG002", "value": "1165.2", "spread": "912.25"}, {"groupId": "OG003", "value": "758.7", "spread": "375.11"}]}]}, {"title": "Day 7, 0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "354.9", "spread": "223.49"}, {"groupId": "OG001", "value": "417.0", "spread": "254.35"}, {"groupId": "OG002", "value": "548.5", "spread": "389.77"}, {"groupId": "OG003", "value": "549.3", "spread": "247.41"}]}]}, {"title": "Day 7, 2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "331.9", "spread": "180.59"}, {"groupId": "OG001", "value": "341.1", "spread": "156.86"}, {"groupId": "OG002", "value": "630.4", "spread": "239.55"}, {"groupId": "OG003", "value": "659.1", "spread": "426.18"}]}]}, {"title": "Day 7, 4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "324.2", "spread": "168.10"}, {"groupId": "OG001", "value": "285.9", "spread": "150.82"}, {"groupId": "OG002", "value": "653.2", "spread": "412.91"}, {"groupId": "OG003", "value": "606.3", "spread": "224.57"}]}]}, {"title": "Day 7, 6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "331.0", "spread": "228.38"}, {"groupId": "OG001", "value": "440.8", "spread": "310.64"}, {"groupId": "OG002", "value": "667.6", "spread": "308.52"}, {"groupId": "OG003", "value": "977.9", "spread": "975.25"}]}]}]}, {"type": "SECONDARY", "title": "Supine Systolic Blood Pressure", "description": "Systolic blood pressure measurements were taken.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "114.8", "spread": "14.10"}, {"groupId": "OG001", "value": "127.0", "spread": "16.62"}, {"groupId": "OG002", "value": "136.1", "spread": "18.80"}, {"groupId": "OG003", "value": "133.2", "spread": "14.79"}]}]}, {"title": "Day 1, 0.5 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "122.8", "spread": "14.36"}, {"groupId": "OG001", "value": "121.5", "spread": "21.78"}, {"groupId": "OG002", "value": "132.9", "spread": "19.52"}, {"groupId": "OG003", "value": "132.5", "spread": "17.85"}]}]}, {"title": "Day 1, 1.0 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "123.9", "spread": "16.53"}, {"groupId": "OG001", "value": "122.2", "spread": "19.20"}, {"groupId": "OG002", "value": "134.1", "spread": "18.57"}, {"groupId": "OG003", "value": "133.2", "spread": "15.22"}]}]}, {"title": "Day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "125.4", "spread": "13.68"}, {"groupId": "OG001", "value": "127.2", "spread": "16.71"}, {"groupId": "OG002", "value": "134.2", "spread": "19.85"}, {"groupId": "OG003", "value": "132.6", "spread": "17.47"}]}]}, {"title": "Day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "133.1", "spread": "18.65"}, {"groupId": "OG001", "value": "130.3", "spread": "17.14"}, {"groupId": "OG002", "value": "140.7", "spread": "20.67"}, {"groupId": "OG003", "value": "142.1", "spread": "17.93"}]}]}, {"title": "Day 1, 8.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "113.6", "spread": "13.29"}, {"groupId": "OG001", "value": "120.9", "spread": "16.85"}, {"groupId": "OG002", "value": "127.3", "spread": "17.39"}, {"groupId": "OG003", "value": "132.2", "spread": "11.40"}]}]}, {"title": "Day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "111.1", "spread": "14.75"}, {"groupId": "OG001", "value": "114.8", "spread": "17.85"}, {"groupId": "OG002", "value": "127.4", "spread": "13.92"}, {"groupId": "OG003", "value": "134.1", "spread": "14.64"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "115.8", "spread": "9.61"}, {"groupId": "OG001", "value": "120.9", "spread": "18.05"}, {"groupId": "OG002", "value": "125.4", "spread": "12.66"}, {"groupId": "OG003", "value": "128.9", "spread": "13.99"}]}]}, {"title": "Day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "110.5", "spread": "10.03"}, {"groupId": "OG001", "value": "115.9", "spread": "15.47"}, {"groupId": "OG002", "value": "128.9", "spread": "14.83"}, {"groupId": "OG003", "value": "128.8", "spread": "13.76"}]}]}, {"title": "Day 7, 0.5 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "116.2", "spread": "10.93"}, {"groupId": "OG001", "value": "122.9", "spread": "11.78"}, {"groupId": "OG002", "value": "127.4", "spread": "16.26"}, {"groupId": "OG003", "value": "130.9", "spread": "15.06"}]}]}, {"title": "Day 7, 1.0 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "117.9", "spread": "10.01"}, {"groupId": "OG001", "value": "124.8", "spread": "12.43"}, {"groupId": "OG002", "value": "127.4", "spread": "17.46"}, {"groupId": "OG003", "value": "130.9", "spread": "15.47"}]}]}, {"title": "Day 7, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "119.3", "spread": "12.70"}, {"groupId": "OG001", "value": "127.5", "spread": "11.95"}, {"groupId": "OG002", "value": "128.6", "spread": "19.35"}, {"groupId": "OG003", "value": "140.7", "spread": "15.89"}]}]}, {"title": "Day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "120.6", "spread": "11.71"}, {"groupId": "OG001", "value": "128.9", "spread": "13.13"}, {"groupId": "OG002", "value": "130.5", "spread": "18.15"}, {"groupId": "OG003", "value": "134.9", "spread": "13.20"}]}]}, {"title": "Day 7, 8.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "111.3", "spread": "12.52"}, {"groupId": "OG001", "value": "119.3", "spread": "10.44"}, {"groupId": "OG002", "value": "123.1", "spread": "12.72"}, {"groupId": "OG003", "value": "130.0", "spread": "15.88"}]}]}, {"title": "Day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "107.9", "spread": "16.70"}, {"groupId": "OG001", "value": "116.5", "spread": "14.85"}, {"groupId": "OG002", "value": "120.3", "spread": "12.60"}, {"groupId": "OG003", "value": "131.9", "spread": "18.71"}]}]}]}, {"type": "SECONDARY", "title": "Supine Diastolic Blood Pressure", "description": "Diastolic blood pressure measurements were taken.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.2", "spread": "9.85"}, {"groupId": "OG001", "value": "74.1", "spread": "13.20"}, {"groupId": "OG002", "value": "77.6", "spread": "10.57"}, {"groupId": "OG003", "value": "74.9", "spread": "9.99"}]}]}, {"title": "Day 1, 0.5 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.2", "spread": "12.00"}, {"groupId": "OG001", "value": "75.5", "spread": "13.77"}, {"groupId": "OG002", "value": "76.3", "spread": "11.85"}, {"groupId": "OG003", "value": "75.8", "spread": "10.67"}]}]}, {"title": "Day 1, 1.0 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.3", "spread": "12.00"}, {"groupId": "OG001", "value": "75.8", "spread": "13.73"}, {"groupId": "OG002", "value": "75.3", "spread": "10.37"}, {"groupId": "OG003", "value": "76.2", "spread": "9.59"}]}]}, {"title": "Day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.3", "spread": "12.01"}, {"groupId": "OG001", "value": "77.1", "spread": "10.61"}, {"groupId": "OG002", "value": "77.6", "spread": "11.79"}, {"groupId": "OG003", "value": "76.0", "spread": "10.78"}]}]}, {"title": "Day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.6", "spread": "13.77"}, {"groupId": "OG001", "value": "79.1", "spread": "12.21"}, {"groupId": "OG002", "value": "80.0", "spread": "13.60"}, {"groupId": "OG003", "value": "79.9", "spread": "9.08"}]}]}, {"title": "Day 1, 8.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.5", "spread": "11.15"}, {"groupId": "OG001", "value": "70.4", "spread": "11.12"}, {"groupId": "OG002", "value": "75.2", "spread": "10.23"}, {"groupId": "OG003", "value": "76.2", "spread": "8.89"}]}]}, {"title": "Day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.4", "spread": "11.49"}, {"groupId": "OG001", "value": "71.7", "spread": "13.43"}, {"groupId": "OG002", "value": "75.5", "spread": "8.33"}, {"groupId": "OG003", "value": "75.7", "spread": "8.81"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.6", "spread": "10.03"}, {"groupId": "OG001", "value": "74.9", "spread": "13.33"}, {"groupId": "OG002", "value": "73.2", "spread": "10.78"}, {"groupId": "OG003", "value": "75.1", "spread": "8.35"}]}]}, {"title": "Day 7, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.9", "spread": "11.04"}, {"groupId": "OG001", "value": "68.4", "spread": "11.37"}, {"groupId": "OG002", "value": "74.7", "spread": "8.77"}, {"groupId": "OG003", "value": "74.7", "spread": "9.62"}]}]}, {"title": "Day 7, 0.5 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.6", "spread": "11.74"}, {"groupId": "OG001", "value": "73.9", "spread": "9.48"}, {"groupId": "OG002", "value": "74.3", "spread": "9.36"}, {"groupId": "OG003", "value": "74.5", "spread": "9.65"}]}]}, {"title": "Day 7, 1.0 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.3", "spread": "10.49"}, {"groupId": "OG001", "value": "73.9", "spread": "8.94"}, {"groupId": "OG002", "value": "73.5", "spread": "8.52"}, {"groupId": "OG003", "value": "75.1", "spread": "8.71"}]}]}, {"title": "Day 7, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "70.6", "spread": "11.85"}, {"groupId": "OG001", "value": "76.7", "spread": "9.15"}, {"groupId": "OG002", "value": "72.0", "spread": "8.20"}, {"groupId": "OG003", "value": "78.8", "spread": "9.29"}]}]}, {"title": "Day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.6", "spread": "11.17"}, {"groupId": "OG001", "value": "74.5", "spread": "10.86"}, {"groupId": "OG002", "value": "74.4", "spread": "9.60"}, {"groupId": "OG003", "value": "78.4", "spread": "9.77"}]}]}, {"title": "Day 7, 8.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "69.3", "spread": "10.08"}, {"groupId": "OG001", "value": "71.5", "spread": "8.43"}, {"groupId": "OG002", "value": "71.4", "spread": "7.84"}, {"groupId": "OG003", "value": "75.3", "spread": "8.50"}]}]}, {"title": "Day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.3", "spread": "10.95"}, {"groupId": "OG001", "value": "69.8", "spread": "12.39"}, {"groupId": "OG002", "value": "70.7", "spread": "8.36"}, {"groupId": "OG003", "value": "75.7", "spread": "11.47"}]}]}]}, {"type": "SECONDARY", "title": "Supine Pulse Rate", "description": "Pulse rate measurements were taken.", "populationDescription": "The Pharmacodynamic (PD) analysis set, which included all participants who had no major protocol deviation with impact on PD data, were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "BPM", "timeFrame": "0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 1; day 2; 0, 0.5, 1, 2, 4, 8 and 12 hours post dose on day 7", "groups": [{"id": "OG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2."}, {"id": "OG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2."}, {"id": "OG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2."}, {"id": "OG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"title": "Day 1, 0.0 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.8", "spread": "8.89"}, {"groupId": "OG001", "value": "61.7", "spread": "14.30"}, {"groupId": "OG002", "value": "65.7", "spread": "9.26"}, {"groupId": "OG003", "value": "65.5", "spread": "8.44"}]}]}, {"title": "Day 1, 0.5 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.3", "spread": "9.34"}, {"groupId": "OG001", "value": "60.7", "spread": "10.45"}, {"groupId": "OG002", "value": "64.1", "spread": "8.59"}, {"groupId": "OG003", "value": "63.4", "spread": "9.29"}]}]}, {"title": "Day 1, 1.0 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.4", "spread": "8.97"}, {"groupId": "OG001", "value": "62.7", "spread": "10.19"}, {"groupId": "OG002", "value": "64.2", "spread": "7.49"}, {"groupId": "OG003", "value": "64.0", "spread": "10.39"}]}]}, {"title": "Day 1, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.0", "spread": "9.02"}, {"groupId": "OG001", "value": "64.3", "spread": "12.39"}, {"groupId": "OG002", "value": "65.6", "spread": "8.28"}, {"groupId": "OG003", "value": "63.2", "spread": "8.89"}]}]}, {"title": "Day 1, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.0", "spread": "8.51"}, {"groupId": "OG001", "value": "62.9", "spread": "13.29"}, {"groupId": "OG002", "value": "64.0", "spread": "6.51"}, {"groupId": "OG003", "value": "65.3", "spread": "9.65"}]}]}, {"title": "Day 1, 8.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "67.6", "spread": "11.70"}, {"groupId": "OG001", "value": "69.1", "spread": "11.34"}, {"groupId": "OG002", "value": "73.9", "spread": "10.20"}, {"groupId": "OG003", "value": "67.5", "spread": "10.09"}]}]}, {"title": "Day 1, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.1", "spread": "13.36"}, {"groupId": "OG001", "value": "62.8", "spread": "10.83"}, {"groupId": "OG002", "value": "73.7", "spread": "13.52"}, {"groupId": "OG003", "value": "65.4", "spread": "9.68"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.1", "spread": "12.18"}, {"groupId": "OG001", "value": "64.5", "spread": "11.95"}, {"groupId": "OG002", "value": "71.3", "spread": "10.58"}, {"groupId": "OG003", "value": "66.5", "spread": "9.20"}]}]}, {"title": "Day 7, 0.0 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.0", "spread": "11.97"}, {"groupId": "OG001", "value": "60.6", "spread": "12.69"}, {"groupId": "OG002", "value": "62.9", "spread": "5.54"}, {"groupId": "OG003", "value": "62.8", "spread": "8.16"}]}]}, {"title": "Day 7, 0.5 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.0", "spread": "12.63"}, {"groupId": "OG001", "value": "60.1", "spread": "12.07"}, {"groupId": "OG002", "value": "63.0", "spread": "4.36"}, {"groupId": "OG003", "value": "61.8", "spread": "9.35"}]}]}, {"title": "Day 7, 1.0 hour post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.3", "spread": "13.21"}, {"groupId": "OG001", "value": "61.6", "spread": "11.70"}, {"groupId": "OG002", "value": "62.3", "spread": "5.87"}, {"groupId": "OG003", "value": "61.6", "spread": "7.70"}]}]}, {"title": "Day 7, 2.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.9", "spread": "10.42"}, {"groupId": "OG001", "value": "58.7", "spread": "11.49"}, {"groupId": "OG002", "value": "61.2", "spread": "6.17"}, {"groupId": "OG003", "value": "63.6", "spread": "9.16"}]}]}, {"title": "Day 7, 4.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.7", "spread": "10.85"}, {"groupId": "OG001", "value": "60.7", "spread": "11.34"}, {"groupId": "OG002", "value": "62.9", "spread": "6.45"}, {"groupId": "OG003", "value": "62.7", "spread": "9.20"}]}]}, {"title": "Day 7, 8.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "67.1", "spread": "10.20"}, {"groupId": "OG001", "value": "66.5", "spread": "11.80"}, {"groupId": "OG002", "value": "66.3", "spread": "7.34"}, {"groupId": "OG003", "value": "64.8", "spread": "10.83"}]}]}, {"title": "Day 7, 12.0 hours post dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.7", "spread": "13.28"}, {"groupId": "OG001", "value": "71.9", "spread": "17.30"}, {"groupId": "OG002", "value": "66.2", "spread": "6.97"}, {"groupId": "OG003", "value": "67.1", "spread": "11.10"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "LCZ696 - Heart Failure (HF) Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 3, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Valsartan - HF Cohort", "description": "Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 1, "otherNumAtRisk": 15}, {"id": "EG002", "title": "LCZ696 - Hypertension (HTN) Cohort", "description": "Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 1, "otherNumAtRisk": 15}, {"id": "EG003", "title": "Valsartan - HTN Cohort", "description": "Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 3, "otherNumAtRisk": 16}], "otherEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 16}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Regarding LSM = 1218.56 for LCZ696 HTN cohort arm at Day 1, 1.0 hr post dose, the value was heavily inflated due to one participant with a very high change from baseline."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis", "phone": "862-778-1873"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}